Evidence Table 111. KQ 3—Continuous Serum potassium

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **CVD Dose (mg/d)** | **Supplement/ Control** | **N** | **Definition of outcome/ Unit of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/% change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Additional Comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Budoff200410Parallel | At high risk for CHD | Statins + aspirin | 10-40 | Garlic | 9 | Unit: mg/dl | NR | Mean: -0.01SD: 1.15 | P:0.7464 | N/A | Medium |
| Placebo | 10 | NR | Mean: -0.15SD: 0.64 |
| Wirell199467Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | Magnesium | 39 | NRmmol/L | Mean: 4SD: 0.3 | NR | P: 0.045 Crude difference | N/A | Medium |
| Placebo | 39 | Mean: 3.9SD: 0.3 | NR |